Prognostic significance of HER3 in patients with malignant solid tumors

被引:44
作者
Li, Qin [1 ]
Zhang, RuiXue [2 ]
Yan, Han [1 ]
Zhao, PengFei [1 ]
Wu, Li [3 ]
Wang, Hui [3 ]
Li, Teng [1 ]
Cao, Bangwei [1 ,4 ,5 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China
[2] Tsinghua Univ, Hosp 1, Dept Internal Med, Beijing 100016, Peoples R China
[3] Shanxi Med Univ, Sch Publ Hlth, Dept Hlth Stat, Taiyuan 030001, Shanxi, Peoples R China
[4] Capital Med Univ, Beijing Friendship Hosp, Beijing Key Lab Precancerous Lesion Digest Dis, Beijing 100050, Peoples R China
[5] Capital Med Univ, Beijing Friendship Hosp, Beijing Digest Dis Ctr, Beijing 100050, Peoples R China
基金
中国国家自然科学基金;
关键词
HER3; malignant tumors; prognosis; molecular markers; immunohistochemistry; BREAST-CANCER; COLORECTAL-CANCER; POOR-PROGNOSIS; MONOCLONAL-ANTIBODY; TYROSINE KINASE; EXPRESSION; OVEREXPRESSION; CARCINOMA; SURVIVAL; AMPLIFICATION;
D O I
10.18632/oncotarget.18007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human epidermal growth factor receptor 3 (HER3) is closely involved in tumor progression and is an important target of therapy. To evaluate the prognostic significance of HER3 in malignant solid tumors, we searched the PUBMED, EMBASE and CNKI databases for relevant studies written in English or Chinese up to December 2015. Fifteen studies comprising 2964 patients were identified. The HER3(+) rate ranged from 9.0-75.1 % in malignant solid tumors: 30.3-75.1 % in breast cancers, 51.1-74.5 % in colorectal cancers, 13.7-59.0 % in gastric cancers, and 54.5-74.4 % in cervical cancers. For patients with a malignant solid tumor, the death risk was higher for those with a HER3(+) tumor than for those with a HER3(-) tumor (HR 1.60, 95% CI: 1.27 - 2.02, P < 0.001). Subgroup analysis revealed this was also the case for patients with digestive or gastric cancer (HR 1.78, P < 0.001; HR 2.18, P < 0.001). By contrast, HER3 had no prognostic significance in colorectal or breast cancer (HR 1.52, P = 0.296; HR 1.23, P = 0.108). HER3(+) is thus associated with poor survival in overall and in gastric cancer. The prognostic significance of HER3(+) in other tumors is uncertain and deserves further study.
引用
收藏
页码:67140 / 67151
页数:12
相关论文
共 51 条
[31]   Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients [J].
Memon, AA ;
Sorensen, BS ;
Melgard, P ;
Fokdal, L ;
Thykjaer, T ;
Nexo, E .
BRITISH JOURNAL OF CANCER, 2004, 91 (12) :2034-2041
[32]   First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors [J].
Meulendijks, Didier ;
Jacob, Wolfgang ;
Martinez-Garcia, Maria ;
Taus, Alvaro ;
Lolkema, Martijn P. ;
Voest, Emile E. ;
Langenberg, Marlies H. G. ;
Fleitas Kanonnikoff, Tania ;
Cervantes, Andres ;
De Jonge, Maja J. ;
Sleijfer, Stefan ;
Soerensen, Morten Mau ;
Thomas, Marlene ;
Ceppi, Maurizio ;
Meneses-Lorente, Georgina ;
James, Ian ;
Adessi, Celine ;
Michielin, Francesca ;
Abiraj, Keelara ;
Bossenmaier, Birgit ;
Schellens, Jan H. M. ;
Weisser, Martin ;
Lassen, Ulrik N. .
CLINICAL CANCER RESEARCH, 2016, 22 (04) :877-885
[33]  
Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]
[34]   Expression of c-erbB3 protein in primary breast carcinomas [J].
Naidu, R ;
Yadav, M ;
Nair, S ;
Kutty, MK .
BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1385-1390
[35]   HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis [J].
Ocana, Alberto ;
Vera-Badillo, Francisco ;
Seruga, Bostjan ;
Templeton, Arnoud ;
Pandiella, Atanasio ;
Amir, Eitan .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (04) :266-273
[36]   Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment [J].
Park, Y. H. ;
Jung, H. A. ;
Choi, M. K. ;
Chang, W. ;
Choi, Y. L. ;
Do, I-g ;
Ahn, J. S. ;
Im, Y-H .
BRITISH JOURNAL OF CANCER, 2014, 110 (02) :384-391
[37]   HER3 is a determinant for poor prognosis in melanoma [J].
Reschke, Markus ;
Mihic-Probst, Daniela ;
van der Horst, Edward Htun ;
Knyazev, Pjotr ;
Wild, Peter J. ;
Hutterer, Markus ;
Meyer, Stefanie ;
Dummer, Reinhard ;
Moch, Holger ;
Ullrich, Axel .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5188-5197
[38]   Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients [J].
Sassen, Andrea ;
Rochon, Justine ;
Wild, Peter ;
Hartmann, Arndt ;
Hofstaedter, Ferdinand ;
Schwarz, Stephan ;
Brockhoff, Gero .
BREAST CANCER RESEARCH, 2008, 10 (01)
[39]   Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab [J].
Scartozzi, M. ;
Giampieri, R. ;
Maccaroni, E. ;
Mandolesi, A. ;
Giustini, L. ;
Silva, R. ;
Zaniboni, A. ;
Biscotti, T. ;
Biagetti, S. ;
Galizia, E. ;
Loupakis, F. ;
Falcone, A. ;
Bearzi, I. ;
Cascinu, S. .
ANNALS OF ONCOLOGY, 2012, 23 (07) :1706-1712
[40]   Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Senkus, E. ;
Kyriakides, S. ;
Penault-Llorca, F. ;
Poortmans, P. ;
Thompson, A. ;
Zackrisson, S. ;
Cardoso, F. .
ANNALS OF ONCOLOGY, 2013, 24 :7-23